Table 1.
Perspectives on MCED testing merit, purpose, and populations for use.
| Perspective | Percent (n/N) of payers who shared this perspective (N = 19) |
|---|---|
| Interest in MCED tests | |
| MCED is of interest to me and/or my organization | 89 (17/19) |
| Interest in MCED from employers | 47 (9/19) |
| Approached by MCED companies | 26 (5/19) |
| Conducting internal MCED pilot with employees | 11 (2/19) |
| Perspectives on scenarios of use | |
| Overall potential merit of MCED | 100 (19/19) |
| Merit of using together with recommended screening for respective cancers | 42 (8/19) |
| Merit of using MCED before recommended screening, as a gateway to increase uptake | 37 (7/19) |
| Merit of using MCED after recommended screening as part of confirmation | 5 (1/19) |
| Merit for use to screen common cancers without recommended screening tests | 84 (16/19) |
| Merit for use to screen rare cancers to increase aggregate diagnostic yield | 53 (10/19) |
| Perspectives on populations for use and potential future coverage | |
| High-risk and/or other specified populations; would not consider MCED for general population screening | 58 (11/19) |
| May be appropriate for general populations if proven by evidence | 42 (8/19) |
Note: Recommended screening: based on U.S. Preventative Task Force (USPSTF) recommendations: mammograms for breast cancer screening, colonoscopies for colorectal cancer screening, low-dose computed tomography scans for lung cancer screening, and cervical cytology for cervical cancer. MCED = multicancer early-detection.